Research programme: cancer therapeutics - OncoMed

Drug Profile

Research programme: cancer therapeutics - OncoMed

Alternative Names: Anti-cancer stem cell monoclonal antibodies - OncoMed; Anti-CSC monoclonal antibodies - OncoMed; Anti-tumour-initiating cell monoclonal antibodies - OncoMed; GITRL-Fc; IO#2; IO#3

Latest Information Update: 19 Aug 2016

Price : $50

At a glance

  • Originator OncoMed Pharmaceuticals
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action DLL4 protein inhibitors; Notch-1 receptor antagonists; Notch-2 receptor antagonists; Notch-3 receptor antagonists; RSPO3 protein inhibitors; Stem cell modulators; TNFRSF18 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 19 Aug 2016 Preclinical development is ongoing in USA in Cancer
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 16 Apr 2016 Pharmacodynamics data from preclinical studies in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top